Disease · MONDO_0005021
Targets28
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 28
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB1 | Adrenergic receptor beta | 5 | Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor beta | 3 | Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist | Phase 1/2 | https://conductscience.org/library/genes/154 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 3 | HMG-CoA reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 2 | Angiotensin-converting enzyme inhibitor | Phase 3 | https://conductscience.org/library/genes/1636 | Drugs and targets |
| ADRA1A | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRB3 | Adrenergic receptor beta | 1 | Adrenergic receptor beta antagonist | Unknown | https://conductscience.org/library/genes/155 | Drugs and targets |
| DRD2 | D2-like dopamine receptor | 1 | D2-like dopamine receptor agonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| DRD3 | D2-like dopamine receptor | 1 | D2-like dopamine receptor agonist | Phase 3 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| DRD4 | D2-like dopamine receptor | 1 | D2-like dopamine receptor agonist | Phase 3 | https://conductscience.org/library/genes/1815 | Drugs and targets |
| GHR | Growth hormone receptor | 1 | Growth hormone receptor agonist | Phase 3 | https://conductscience.org/library/genes/2690 | Drugs and targets |
| HCN4 | Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 | 1 | Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker | Phase 2 | https://conductscience.org/library/genes/10021 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 1 | Histamine H1 receptor antagonist | Unknown | https://conductscience.org/library/genes/3269 | Drugs and targets |
| MAPK14 | Mitogen-activated protein kinase 14 | 1 | MAP kinase p38 alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/1432 | Drugs and targets |
| MYH6 | Cardiac myosin | 1 | Cardiac myosin activator | Phase 2/3 | https://conductscience.org/library/genes/4624 | Drugs and targets |
| MYH7 | Cardiac myosin | 1 | Cardiac myosin activator | Phase 2/3 | https://conductscience.org/library/genes/4625 | Drugs and targets |
| MYH7B | Cardiac myosin | 1 | Cardiac myosin activator | Phase 2/3 | https://conductscience.org/library/genes/57644 | Drugs and targets |
| MYL2 | Cardiac myosin | 1 | Cardiac myosin activator | Phase 2/3 | https://conductscience.org/library/genes/4633 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005021/targets